Trump proposed a change to Medicare price talks that has long been sought after by the pharmaceutical industry.

With the American Association for Cancer Research’s annual conference now underway, oncology researchers can expect ...

Boehringer Ingelheim unveiled new data from its top oncology prospect zongertinib, further backing the drug’s prowess in ...

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced ...

A new survey shows animal owners deeply appreciate veterinarians, but challenges like work-life balance and emotional strain remain widely misunderstood.

Zongertinib, an oral therapy shown to have strong responses in patients previously treated for HER2 -mutated non–small cell ...

Presentations at this year’s American Association for Cancer Research meeting could have a broad impact on the treatment ...

Zongertinib elicited meaningful results in previously treated patients with HER2-mutated, advanced non–small cell lung cancer ...

Company prepares new product launches starting in 2025.

Boehringer Ingelheim and Tessellate Bio have entered into a partnership worth over €500m to develop oral precision medicines ...